HC Wainwright Lowers Aprea Therapeutics (NASDAQ:APRE) Price Target to $5.00

Aprea Therapeutics (NASDAQ:APRE) had its price objective cut by analysts at HC Wainwright from $20.00 to $5.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 442.89% from the company’s current price.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Aprea Therapeutics presently has a consensus rating of “Hold” and an average price target of $8.00.

Aprea Therapeutics Stock Performance

NASDAQ APRE traded up $0.01 during trading hours on Thursday, reaching $0.92. 17,589 shares of the company’s stock were exchanged, compared to its average volume of 51,828. The company has a market capitalization of $5.81 million, a price-to-earnings ratio of -0.43 and a beta of 1.23. The company’s 50-day moving average is $1.25 and its two-hundred day moving average is $1.52. Aprea Therapeutics has a one year low of $0.90 and a one year high of $5.00.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.36). Aprea Therapeutics had a negative net margin of 2,666.46% and a negative return on equity of 88.12%. The company had revenue of $0.00 million during the quarter. Research analysts predict that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Insider Transactions at Aprea Therapeutics

In other news, Director Marc Duey bought 21,459 shares of the company’s stock in a transaction dated Wednesday, December 10th. The stock was bought at an average cost of $1.17 per share, for a total transaction of $25,107.03. Following the transaction, the director owned 256,155 shares of the company’s stock, valued at $299,701.35. This represents a 9.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 13.63% of the stock is owned by corporate insiders.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.